ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Phase II Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
Case Medical Research
◽
10.31525/ct1-nct03939871
◽
2019
◽
Author(s):
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Study
◽
Advanced Breast
◽
Oral Vinorelbine
◽
Hormone Receptor Positive
Download Full-text
Related Documents
Cited By
References
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-18-0613
◽
2018
◽
Vol 24
(18)
◽
pp. 4380-4387
◽
Cited By ~ 26
Author(s):
Maura N. Dickler
◽
Cristina Saura
◽
Donald A. Richards
◽
Ian E. Krop
◽
Andrés Cervantes
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Study
◽
Advanced Breast
◽
Hormone Receptor Positive
Download Full-text
Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial)
10.1158/1538-7445.sabcs15-ot3-02-04
◽
2016
◽
Cited By ~ 1
Author(s):
J De la Haba
◽
M Cazzaniga
◽
G Freyer
◽
L Costa
◽
E Petru
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Study
◽
Single Agent
◽
First Line
◽
Oral Vinorelbine
◽
Hormone Receptor Positive
◽
Line Chemotherapy
Download Full-text
Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis byPIK3CAandESR1mutation status from circulating tumor DNA
10.1158/1538-7445.sabcs16-p6-12-01
◽
2017
◽
Cited By ~ 2
Author(s):
MN Dickler
◽
C Saura
◽
M Oliveira
◽
DA Richards
◽
IE Krop
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Study
◽
Circulating Tumor Dna
◽
Advanced Breast
◽
Hormone Receptor Positive
◽
Tumor Dna
Download Full-text
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
European Journal of Cancer
◽
10.1016/j.ejca.2021.11.010
◽
2022
◽
Vol 161
◽
pp. 26-37
Author(s):
J. Albanell
◽
M.T. Martínez
◽
M. Ramos
◽
M. O'Connor
◽
L. de la Cruz-Merino
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Study
◽
Advanced Breast
◽
Hormone Receptor Positive
◽
Randomized Phase Ii
Download Full-text
Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash.
Journal of Clinical Oncology
◽
10.1200/jco.2014.32.15_suppl.tps661
◽
2014
◽
Vol 32
(15_suppl)
◽
pp. TPS661-TPS661
◽
Cited By ~ 1
Author(s):
Hope S. Rugo
◽
Mark Steven Chambers
◽
Jennifer Keating Litton
◽
Ingrid A. Mayer
◽
Jaqueline Willemann Rogerio
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Study
◽
Advanced Breast
◽
Hormone Receptor Positive
Download Full-text
A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.520
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. 520-520
◽
Cited By ~ 18
Author(s):
Maura N. Dickler
◽
Cristina Saura
◽
Donald A. Richards
◽
Ian E. Krop
◽
Andres Cervantes
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Study
◽
Advanced Breast
◽
Pi3k Inhibitor
◽
Hormone Receptor Positive
Download Full-text
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
Contemporary Clinical Trials Communications
◽
10.1016/j.conctc.2018.05.012
◽
2018
◽
Vol 10
◽
pp. 190-192
Author(s):
Filipa Lynce
◽
Mervat Saleh
◽
Ayesha Shajahan-Haq
◽
Christopher Gallagher
◽
Asma Dilawari
◽
...
Keyword(s):
Breast Cancer
◽
African American
◽
Advanced Breast Cancer
◽
African American Women
◽
Phase Ii
◽
Hormone Receptor
◽
Advanced Breast
◽
Safety Study
◽
American Women
◽
Hormone Receptor Positive
Download Full-text
Abstract P1-14-01: Final results of NorBreast-231, a randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel as first-line chemotherapy in patients with advanced breast cancer
10.1158/1538-7445.sabcs18-p1-14-01
◽
2019
◽
Author(s):
MS Aapro
◽
R Hegg
◽
M Ruiz Borrego
◽
E Staroslawska
◽
S Morales
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Phase Ii Study
◽
Advanced Breast
◽
Weekly Paclitaxel
◽
First Line
◽
Oral Vinorelbine
◽
Randomized Phase Ii
◽
Line Chemotherapy
Download Full-text
Abstract OT2-01-09: PALINA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer
10.1158/1538-7445.sabcs16-ot2-01-09
◽
2017
◽
Author(s):
F Lynce
◽
A Shajahan-Haq
◽
L Cai
◽
D Graham
◽
C Gallagher
◽
...
Keyword(s):
Breast Cancer
◽
African American
◽
Advanced Breast Cancer
◽
African American Women
◽
Phase Ii
◽
Hormone Receptor
◽
Advanced Breast
◽
Safety Study
◽
American Women
◽
Hormone Receptor Positive
Download Full-text
Abstract P2-10-01: Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer
10.1158/1538-7445.sabcs18-p2-10-01
◽
2019
◽
Author(s):
A Zhu
◽
P Yuan
◽
J Wang
◽
Y Fan
◽
Y Luo
◽
...
Keyword(s):
Breast Cancer
◽
Tyrosine Kinase
◽
Advanced Breast Cancer
◽
Tyrosine Kinase Inhibitor
◽
Phase Ii
◽
Kinase Inhibitor
◽
Phase Ii Study
◽
Advanced Breast
◽
Oral Vinorelbine
◽
Heavily Pretreated
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close